ubmslateRN-logo-ubm

RN Mobile Menu

Search form

Topics:

Myositis

Will You Buy In on the Next Biosimilar?

The FDA has deferred a scheduled meeting about Remsima, the infliximab biosimilar already approved in Europe and still awaiting judgment in the US. But approval of the first US biosimilar (a version of the cancer drug filgrastim) prompted warnings from two organizations concerned with rheumatic disease, including the ACR. Are you ready the next challenge to your clinical judgment?

Myositis

A comprehensive review has compiled and summarized all current information about pathology, diagnosis, and treatment of the various subsets of myositis.

scleroderma

A general overview of the fibrosis process discusses mechanisms and cell pathways in brief while focusing on clinical issues.

About 30% of rheumatologists don't pre-test patients for hepatitis B before prescribing immunosuppressant medications. These authors offer new guidance for screening.

The increased risk for venous thromoboembolism after surgery among patients with rheumatic disease appears to trace to those conditions with a clotting component. However, joint surgery in general has a high risk of this complication.

Norman B. Gaylis MD

A Miami rheumatologist tells why he has donated $1 million to offer his colleagues in community practice the chance to pursue their own clinical theories.

prior authorization

Prior authorizations have begun to spread pandemic-like from high-cost biologics to treatments used routinely in rheumatology. The time burden on rheumatologists is insupportable, contends the author, who says it's time to take action.

Pages

Subscribe to Myositis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.